NCT00175695View on ClinicalTrials.gov

Disease Modification in Toxaemia of Pregnancy

CompletedOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

October 31, 2010

Study Completion Date

October 31, 2010

Conditions
Pre-eclampsia
Interventions
DRUG

Recombinant human activated protein C or drotrecogin alpha

We are going to investigate a compound (recombinant human activated protein C (rhAPC)) that has the potential to modify disease activity in pre-eclampsia by reducing coagulation and inflammation disorders.

Trial Locations (1)

V6H 3N1

BC Women's Hospital and Health Centre, Vancouver

All Listed Sponsors
lead

University of British Columbia

OTHER

NCT00175695 - Disease Modification in Toxaemia of Pregnancy | Biotech Hunter | Biotech Hunter